Literature DB >> 24043245

Evaluation of an enoxaparin dosing calculator using burn size and weight.

Iris Faraklas1, Maureen Ghanem, Amalia Brown, Amalia Cochran.   

Abstract

Previous research has shown that inadequate antifactor Xa levels (anti-Xa) occur in burn patients and may increase the risk of venous thromboembolic events (VTE). The objective of this retrospective review was to investigate the usefulness of an enoxaparin dosing algorithm using a previously published equation. With institutional review board approval, all acute burn patients at an American Burn Association-verified regional burn center who were treated with enoxaparin for VTE prophylaxis and had at least one anti-Xa from May 1, 2011 to December 15, 2012 were included. Patients with subprophylactic anti-Xa received increased enoxaparin dose per unit protocol with the goal of obtaining a prophylactic anti-Xa (0.2-0.4 U/ml). Sixty-four patients were included in our analysis. The regression equation was used in 33 patients for initial enoxaparin dosing (Eq) whereas 31 patients received traditionally recommended prophylaxis dosing (No-Eq). Groups were comparable in sex, age, weight, inhalation injury, and burn size. Initial enoxaparin dosing in Eq was significantly more likely to reach target than in No-Eq (73 vs 32%; P = .002). No episodes of hemorrhage, thrombocytopenia, or heparin sensitivity were documented in either group. Median final enoxaparin dose required to reach prophylactic level was 40 mg every 12 hours (range, 30-80 mg). Twenty-one No-Eq patients ultimately reached target, and 11 of these final doses were equivalent to or greater than the predicted equation. Ten patients never reached prophylactic anti-Xa before enoxaparin was discontinued (nine from No-Eq). Two patients, one from each group, developed VTE complications despite appropriate anti-Xa for prophylaxis. A strong correlation was shown between weight, burn size, and enoxaparin dose (r = .68; P < .001). Use of the enoxaparin dosing algorithm significantly increased the frequency of obtaining a target initial anti-Xa. There were no bleeding complications. Enoxaparin dosing correlates to burn size and weight, making a standard dose inappropriate because patient habitus and extent of burn injury are highly variable. This simple equation improves enoxaparin dosing for acute adult burn patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24043245     DOI: 10.1097/BCR.0b013e3182a2a855

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  3 in total

1.  Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.

Authors:  Christopher J Pannucci; Kory I Fleming; Corinne B Bertolaccini; Ann Marie Prazak; Lyen C Huang; T Bartley Pickron
Journal:  JAMA Surg       Date:  2019-08-01       Impact factor: 14.766

2.  Intravenous Enoxaparin in Pediatric Burn Patients: A Case Series.

Authors:  Vonya N Streetz; Leslie K Patatanian
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Sep-Oct

3.  Impact of Platelets and Platelet-Derived Microparticles on Hypercoagulability Following Burn Injury.

Authors:  Emily F Midura; Joshua W Kuethe; Teresa C Rice; Rosalie Veile; Lisa G England; Lou Ann Friend; Charles C Caldwell; Michael D Goodman
Journal:  Shock       Date:  2016-01       Impact factor: 3.454

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.